Janssen Pharmaceutical Companies of Johnson & Johnson, High Wycombe, UK.
Janssen Pharmaceutical Companies of Johnson & Johnson, Spring House, Pennsylvania, USA.
Toxicol Pathol. 2022 Jul;50(5):548-551. doi: 10.1177/01926233221106695. Epub 2022 Jun 29.
Nonhuman primates (NHPs) are utilized in nonclinical safety testing due to their phylogenetic proximity to humans and similarity in physiology and anatomy. However, ethical considerations and the increased demand for NHPs, coupled with the current shortage in their supply, have increased the calls to minimize their use. In addition, the increased demand and supply shortage of NHPs have increased the use of animals sourced from different geographical origins, and animals of different ages, which can complicate the interpretation of study results. Coupled with the relative uniqueness of findings induced by novel therapeutic modalities, there is an increasing need for a deeper understanding of the systemic pathobiology of NHPs. Here we provide a brief preview of the two main themes discussed in this special issue, which include the influence of geographical origin, age, and sex on background pathology, clinical pathology reference values, other relevant toxicology endpoints, and organ system pathology.
非人类灵长类动物（NHPs）由于与人类在进化上的亲缘关系以及在生理学和解剖学上的相似性，被用于非临床安全性测试。然而，出于伦理方面的考虑，以及对 NHPs 的需求增加，再加上它们目前的供应短缺，人们越来越呼吁尽量减少对它们的使用。此外，NHPs 的需求增加和供应短缺增加了来自不同地理来源和不同年龄的动物的使用，这可能会使研究结果的解释复杂化。再加上新型治疗方式引起的发现相对独特，人们越来越需要更深入地了解 NHPs 的系统病理生物学。在这里，我们简要介绍了本期特刊中讨论的两个主要主题，包括地理来源、年龄和性别对背景病理学、临床病理学参考值、其他相关毒理学终点以及器官系统病理学的影响。
